Skip to Content

MACs to issue final LCDs for skin substitute products effective Jan. 1, 2026 

MACs to issue final LCDs for skin substitute products effective Jan. 1, 2026 

WASHINGTON – The seven A/B Medicare Administrative Contractors (MACs) will release updated final Local Coverage Determinations (LCDs) for skin substitute grafts and cellular/tissue-based products used to treat diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) that will be effective Jan. 1, 2026, according to a Dec. 15 Fact Sheet from the Centers for Medicare & Medicaid Services (CMS)

Key highlights of the LCDs 

  • Expanded access: Medicare beneficiaries with DFUs and VLUs will have access to multiple evidence-based skin substitute products. 
  • Scope: LCDs apply only to DFU and VLU indications; they do not affect payment for other uses. 
  • Utilization controls: Frequency and usage limits are included to promote patient safety and ensure reasonable use. 

Background and process 

  • CMS delayed the original LCD effective date under the Trump Administration to allow for a comprehensive review and stakeholder input. 
  • A six-month evidence submission period ended Nov. 1, 2025, with CMS receiving data for 66 products. 
  • Products were categorized into three groups:  
    • Covered: Products meeting evidence standards; covered starting Jan. 1, 2026. 
    • Non-covered: Products lacking sufficient evidence or ongoing research. 
    • 12-month status quo: Products with interim results or active clinical trials; MACs may pay claims at their discretion during this period. 

At the end of the 12-month status quo period (Dec. 31, 2026), MACs will reconsider coverage based on new evidence. A revised LCD is expected in early 2027. 

Current coverage snapshot 

  • 18 products identified as covered (including one with new 2025 research). 
  • 154 products fall under MAC discretion during the status quo period. 

Additional resources 

Comments

To comment on this post, please log in to your account or set up an account now.